Spirapril

Drug Profile

Spirapril

Alternative Names: Cardiopril; Quadropril; Renormax; Renpress; SCH 33844; Setrilan; TI 211950

Latest Information Update: 19 Aug 2016

Price : $50

At a glance

  • Originator Schering-Plough
  • Developer Italfarmaco; Meda; Merck & Co; Novartis
  • Class Antihypertensives; Dipeptides; Heart failure therapies
  • Mechanism of Action ACE inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Heart failure; Hypertension

Most Recent Events

  • 05 Aug 2016 Meda has been acquired by Mylan
  • 22 Aug 2000 A clinical study has been added to the Heart Failure pharmacodynamics section
  • 18 Nov 1999 A study has been added to the Hypertension therapeutic use section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top